ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report)'s share price rose 5.8% during mid-day trading on Tuesday . The company traded as high as $8.74 and last traded at $8.71. Approximately 42,644 shares changed hands during trading, a decline of 92% from the average daily volume of 538,831 shares. The stock had previously closed at $8.23.
Wall Street Analysts Forecast Growth
ORIC has been the topic of a number of recent analyst reports. Wedbush lifted their price target on shares of ORIC Pharmaceuticals from $12.00 to $20.00 and gave the company an "outperform" rating in a research report on Friday, March 1st. HC Wainwright boosted their target price on shares of ORIC Pharmaceuticals from $15.00 to $21.00 and gave the stock a "buy" rating in a research report on Thursday, March 21st. Cantor Fitzgerald began coverage on shares of ORIC Pharmaceuticals in a report on Friday, February 23rd. They set an "overweight" rating for the company. Finally, JPMorgan Chase & Co. dropped their price objective on ORIC Pharmaceuticals from $19.00 to $18.00 and set an "overweight" rating on the stock in a research note on Wednesday, March 27th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $19.80.
View Our Latest Stock Analysis on ORIC
ORIC Pharmaceuticals Price Performance
The firm has a market cap of $595.32 million, a P/E ratio of -4.56 and a beta of 1.04. The company's 50 day moving average is $12.07 and its two-hundred day moving average is $9.80.
ORIC Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last issued its earnings results on Monday, March 11th. The company reported ($0.49) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.49). Research analysts predict that ORIC Pharmaceuticals, Inc. will post -1.75 EPS for the current year.
Insider Activity
In other ORIC Pharmaceuticals news, CEO Jacob Chacko sold 13,958 shares of the firm's stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $12.12, for a total transaction of $169,170.96. Following the transaction, the chief executive officer now owns 794,586 shares in the company, valued at $9,630,382.32. The sale was disclosed in a document filed with the SEC, which is available through this link. 5.34% of the stock is currently owned by company insiders.
Institutional Trading of ORIC Pharmaceuticals
A number of large investors have recently made changes to their positions in ORIC. AJOVista LLC bought a new stake in shares of ORIC Pharmaceuticals in the fourth quarter worth about $40,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of ORIC Pharmaceuticals in the 4th quarter valued at approximately $58,000. Strs Ohio bought a new stake in ORIC Pharmaceuticals during the 4th quarter worth approximately $72,000. Sherbrooke Park Advisers LLC acquired a new stake in ORIC Pharmaceuticals during the 3rd quarter worth approximately $72,000. Finally, Algert Global LLC bought a new position in ORIC Pharmaceuticals in the third quarter valued at approximately $81,000. Institutional investors own 95.05% of the company's stock.
About ORIC Pharmaceuticals
(
Get Free Report)
ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.
Featured Articles
Before you consider ORIC Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ORIC Pharmaceuticals wasn't on the list.
While ORIC Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
